Synceptor

Engineered protein therapeutics for metabolic disease

Synceptor, Inc. is a preclinical-stage biotechnology company in San Diego. We design and develop engineered protein therapeutics for obesity, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH).

Our approach

Our name describes how we design medicines: synergistic, synthetic and synchronous receptor targeting. We engineer protein therapeutics that act on more than one metabolic hormone pathway from a single molecule, using receptor pharmacology, protein engineering and computational design.

Synergistic

Engineered ligands with a balanced, selective receptor activation profile, keeping metabolic benefits while limiting signaling linked to unwanted effects.

Synthetic

Designed molecules that combine the activities of complementary metabolic hormone pathways, a pairing not found together in any single natural hormone.

Synchronous

Both activities are delivered by a single molecule, engaging the two pathways at the same time and in the same tissues for a coordinated metabolic response.

Focus

We are developing therapeutics for obesity, type 2 diabetes and MASH. Our lead program is a first-in-class therapeutic directed at a novel target, and our molecules are designed for a differentiated therapeutic profile.

Target therapeutic profile

Balanced weight loss

Combines reduced food intake with increased energy expenditure, rather than relying on appetite suppression alone.

Lean mass preservation

Weight loss driven predominantly by loss of fat, with lean mass preserved on body composition imaging.

Durable weight loss

Limited weight regain in nonhuman primates, consistent with a potential first-in-class mechanism acting on the central melanocortin pathway that governs long-term energy balance.

Gastrointestinal tolerability

Minimal delay in gastric emptying and low taste aversion in preclinical models compared with the GLP-1 receptor agonist class.

Long-acting pharmacology

Extended half-life in nonhuman primates, supporting potentially infrequent dosing.

Glycemic control

Robust glucose lowering and improved insulin sensitivity.

Liver fat and lipids

Reductions in liver fat and circulating cholesterol, relevant to MASH and cardiometabolic risk.

Profile based on preclinical studies in rodents and nonhuman primates. Our therapeutics have not been evaluated in humans.

Team

Synceptor's founding team brings more than 75 years of combined research experience in metabolic disease, with scientific training at Harvard, UC Berkeley and the Salk Institute. The team has a track record in biologics discovery and development, including advancing multiple programs from concept into clinical trials.

Scientific advisory board

Ronald M. Evans, PhD

Professor and Director, Gene Expression Laboratory, Salk Institute. Member, National Academy of Sciences and National Academy of Medicine.

Chih-Hao Lee, PhD

Distinguished Professor, Genomics Research Center, Academia Sinica. Formerly Professor, Harvard T.H. Chan School of Public Health.

Rohit Loomba, MD, MHSc

Professor of Medicine, Chief of Gastroenterology and Hepatology, and Founding Director, MASLD Research Center, UC San Diego.

Contact

We welcome inquiries from prospective partners, investors and collaborators.

Use the form to reach our team. We will reply by email.

Address

Synceptor, Inc.
BioLabs San Diego
9276 Scranton Rd, Suite 500
San Diego, CA 92121